Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2007

View Archived Issues

AstraZeneca reviews development and regulatory advances of fourth quarter

Novel tubulin polymerization inhibitors identified at Threshold Pharmaceuticals

CNTO-1275 effective in phase II psoriasis trial

Lacosamide significantly reduces pain in peripheral diabetic neuropathy

New treatment option for urological disorders disclosed in recent Ranbaxy patent

Novel anticancer agents imparted in recent Novartis patent

Recent patents describe new therapeutic agents for neurological disorders

Recent patents describe novel analgesic agents

Long-acting octreotide to be investigated in polycystic liver disease

FG-4539 neuroprotective in stroke model

Studies support phase III investigations of ancrod in stroke

Kadian pharmacokinetics not significantly affected by alcohol

Forbes Medi-Tech restructures

Avanex announces preclinical oncology compounds

R-763 studied in phase I for hematological malignancies

Phase III clinical trial under way for LymphoStat-B in SLE

Poniard seeks to begin clinical testing of oral picoplatin

Elixir and Siena Biotech collaborate on SIRT1 inhibitors in Huntington's disease

BL-1020 successfully completes phase I trials for schizophrenia

Seattle Genetics awarded orphan drug designations for SGN-33 and SGN-35

GW and Otsuka establish strategic cannabinoid alliance

Hemospan studied in parallel European phase III trials

TG-4040 studied in phase I trial for chronic HCV

Silenor NDA filing on track for Q3 2007

ThromboView phase II DVT results confirm efficacy

DDP-733 produces statistically significant clinical response rate in IBS-c

AzaSite Plus well tolerated in phase I study

Replagal launching in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...